We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Certain Cytokines Not Associated with Severity of COVID-19 Symptoms

By LabMedica International staff writers
Posted on 24 Jun 2020
Print article
Image: This illustration reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically (Photo courtesy of Centers for Disease Control and Prevention).
Image: This illustration reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically (Photo courtesy of Centers for Disease Control and Prevention).
The pandemic outbreak of coronavirus disease 2019 (COVID-19) is sharply spreading all over the world. The severity of a viral disease usually is positive association with immune-mediated inflammatory responses. The aggressive and persistent inflammatory response leads to high risk of multiorgan failure and death.

The overproduction inflammatory cytokines results in cytokine storm. Cytokine storm indicates excessive release of pro-inflammatory cytokines including C-reactive protein (CRP) and pro-inflammatory cytokines (IL-2, IL-4, TNF-α, IFN-γ). There is a body of evidences suggests that severe COVID-19 patients have cytokine storm.

Scientists at the Harbin Medical University (Harbin, China) and their colleagues studied patients aged 39 to 85 years old, who were confirmed to be SARS-CoV-2 positive via nasopharyngeal swabs. Further, clinical characteristics and chest CT scans indicated that these patients had severe COVID-19. All patients were admitted in ICU with hypoxemic respiratory failure. Of these patients, five (20%) had hypertension and five (20%) had diabetes. All 25 patients were discharged from the ICU to the hospital ward before being discharged home.

The scientists analyzed serum inflammatory cytokines and immune cells in these patients and found that CRP (range: 0.499-9.75 mg/L; reference value: 0-10 mg/L), IL-2 (range: 0.67-2.59 pg/L; reference value: 0.08-5.71 pg/mL), IL-4 (range: 0-2.27 pg/L; reference value: 0.1-2.8 pg/L), TNF-α (range: 0-1.86 pg/L; reference value: 0.1-2.31 pg/L) and IFN-γ (range: 0.51-3.24 pg/L; reference value: 0.16-7.42 pg/L) were in the normal value range compared to the reference value. These cases showed that IL-2, IL-4, TNF-α, IFN-γ and C reactive protein level is not associated with severe COVID-19 pathology.

The investigators also reported that levels of IL-6 and IL-10 in some severe COVID-19 patients were over the reference values, indicating that these patients had severe clinical characteristics independent of circulating levels of IL-2, IL-4, TNF-α, IFN-γ and CRP. IL-6 levels in 16 patients were above the reference range of 1.18-5.3 pg/L, with levels of 0-36.3 pg/L recorded in all 25 patients. In addition, 14 patients had IL-10 levels above the reference range of 0.19-4.91 pg/L, with levels of 4.96-12.44 pg/L observed across the 25 patients.

The authors concluded that some reports had shown cytokine storm was correlated with severity and mortality of COVID-19 patients, but the correlation does not indicate causation. More viral replication also could drive consequent severity of COVID-19. The authors said that the hypothesis that blocking cytokine storm eases COVID-19 severity needs to be more carefully investigated based on their observation. The study was published on June 10, 2020 in the Journal of Medical Virology.

Related Links:
Harbin Medical University

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.